RT Journal Article
SR Electronic
T1 Late Breaking Abstract - A connected inhaler system improves adherence to fluticasone furoate/vilanterol in asthma
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP OA3561
DO 10.1183/13993003.congress-2019.OA3561
VO 54
IS suppl 63
A1 Alison Moore
A1 Andrew Preece
A1 Raj Sharma
A1 Liam G Heaney
A1 Richard W Costello
A1 Robert Wise
A1 Andrea Ludwig-Sengpiel
A1 Giselle Mosnaim
A1 Jamie Rees
A1 Ryan Tomlinson
A1 Ruth Tal-Singer
A1 Neil Barnes
YR 2019
UL http://erj.ersjournals.com/content/54/suppl_63/OA3561.abstract
AB Background: Poor adherence is a key factor in poor asthma control. A connected inhaler system (CIS) comprising sensors on inhalers, a patient-facing app, and a Healthcare Professional (HCP) dashboard could improve asthma management by improving adherence.Methods: Study 207040 (NCT033800429) is one of the first to investigate the different elements of a CIS in improving adherence. The study had a 24-week, open-label, randomised, multi-centre, parallel group design with 5 treatment arms, in uncontrolled asthmatic patients [Asthma Control Test (ACT) <20] on fixed dose ICS/LABA maintenance therapy. All participants (n=437) received fluticasone furoate/vilanterol Ellipta DPI maintenance therapy, and salbutamol MDI rescue therapy with Propeller Health® sensors attached. Participants were randomised to one of 5 treatment arms: data on (1) maintenance use to participant and HCP; (2) maintenance use to participant; (3) maintenance and rescue use to participant and HCP; (4) maintenance and rescue use to participant; or (5) no data to participant or HCP (control arm).Results: The primary endpoint was the effect of 6 months’ use of a CIS on adherence to maintenance therapy assessed over months 4-6, with the absolute adjusted mean adherence difference in arm 1 (data on maintenance to participant and HCP; 82.0%) being 13.2% (95% CI [6.3%, 20.0%]; p<0.001) greater than arm 5 (control; 68.8%). For arms 2, 3 and 4 the adjusted mean differences were 9.0%, 9.8% and 8.9% respectively versus arm 5 (all statistically significant at the 5% level).Conclusion: The study demonstrates that a CIS can improve adherence to maintenance medication for patients with uncontrolled asthma.Funding: GlaxoSmithKline plc. (207040)FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, OA3561.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).